Document is current
Any future updates will be listed below
-
Authors
McCurdy, Jeffrey D. http://orcid.org/0000-0002-0658-3062
Crooks, Patrick
Gwaltney, Chad
Krupnick, Robert
Cadogan, Kathy-Ann
Karki, Chitra
-
Funding
Funding for this research was provided by:
Takeda Pharmaceuticals U.S.A. (Takeda Pharmaceuticals U.S.A.)
- License Information
-
More Information
Article History
Received: 15 January 2024
Accepted: 1 May 2024
First Online: 22 August 2024
Change Date: 9 October 2024
Change Type: Update
Change Details: The original Additional file contained notes from the peer review stage. It has been updated to remove these comments.
Declarations
:
: Ethical approval was granted by the New England Independent Review Board. The study was conducted in accordance with ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practice and applicable regulatory requirements. The study was conducted in accordance with the regulations of the FDA as described in 21 CFR 50 and 56, applicable laws, and the independent review board (IRB) requirements (). Protocol revisions were communicated to the IRB for review and approval before implementation. Patients provided signed informed consent prior to participation. The CCFQ-20<sup>™</sup> is copyright of Takeda Pharmaceuticals 2022.
: Not applicable.
: Jeffrey D. McCurdy has received honorarium/speaker fees from AbbVie, BMS, Fresenius Kabi, Janssen, Pfizer and Takeda. Patrick Crooks and Robert Krupnick are employees of IQVIA Real World Solutions. IQVIA Real World Solutions received funding from Takeda for the completion of this study. Chad Gwaltney has received consulting fees from IQVIA Real World Solutions. Chitra Karki is an employee and shareholder of Takeda Pharmaceuticals USA, Inc. Kathy-Ann Cadogan was an employee and shareholder of Takeda Pharmaceuticals USA, Inc. at the time of the study.
